Depression and anxiety<unk>  shows efficacy against serious depressive episodes (major depression), comparable to amitriptyline, imipramine and fluoxetine, but with significantly fewer side effects. It was shown to be more effective than maprotiline in a group of people with co-existing depression and anxiety.<unk>  also displays significant anxiolytic properties and is useful in treating a spectrum of anxiety disorders including panic disorder, as evidenced by a study in which those administered 35% CO2 gas (carbogen) on paroxetine or<unk>  therapy showed equivalent panic-blocking effects. Like many antidepressants (including bupropion, the selective serotonin reuptake inhibitors, the serotonin-norepinephrine reuptake inhibitors, moclobemide and numerous others) it may also have a beneficial effect on cognition in people with depression-induced cognitive dysfunction. A 2005 study in Egypt showed<unk>  to be effective in men with depression and erectile dysfunction.<unk>  has been found to be effective in depression, in people with Parkinson's disease, and with post-traumatic stress disorder for which it was as safe and effective as fluoxetine and moclobemide. Other uses A clinical trial comparing its efficacy and tolerability with amitriptyline in the treatment of irritable bowel syndrome showed that<unk>  was at least as effective as amitriptyline and produced fewer prominent adverse effects, such as dry mouth and constipation.<unk>  has been reported to be very effective for asthma. In August 1998, Dr. Fuad Lechin and colleagues at the Central University of Venezuela Institute of Experimental Medicine in Caracas published the results of a 52-week randomized controlled trial of asthmatic children; the children in the groups who received<unk>  had a sharp decrease in clinical rating and increased lung function. Two years earlier, they had found a close, positive association between free serotonin in plasma and severity of asthma in symptomatic persons. As<unk>  was the only agent known to both reduce free serotonin in plasma and enhance uptake in platelets, they decided to use it to see if reducing free serotonin levels in plasma would help. By November 2004, there had been two double-blind placebo-controlled crossover trials and an under-25,000 person open-label study lasting over seven years, both showing effectiveness.<unk>  also has anticonvulsant and analgesic effects, and a clinical trial in Spain that ended in January 2007 has shown that<unk>  is effective in treating pain due to fibromyalgia.<unk>  has been shown to have efficacy with minimal side effects in the treatment of attention-deficit hyperactivity disorder.
Tianeptine
Droperidol
Galantamine
Rivastigmine
Cupiennin
Gliquidone
Tripelennamine
Bromperidol decanoate